Vertex Pharma (VRTX): Focus on Cystic Fibrosis - Leerink
Tweet Send to a Friend
Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Vertex (NASDAQ: VRTX) noting that the near-term catalysts ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE